In the SUSTAIN 6 trial, a two-year cardiovascular outcomes study, semaglutide was linked to a significant increase in DR risk compared to the placebo [25]
Under the PBS, eligible patients can receive a substantial subsidy, lowering the out-of-pocket costs for semaglutide prescriptions
VEGFR-2, primarily expressed in endothelial cells, is a tyrosine kinase receptor for VEGF, playing a pivotal role in angiogenesis
Combination therapies that unify the benefits of SGLT2 inhibition with other glucose-lowering mechanisms (like GLP-1 agonism) are also in development to provide multifaceted treatment approaches
The human efficacy record is mixed: the fragment cleared safety trials but missed its primary weight endpoint in its largest study, and development for obesity stopped in 2007
Serious side effects are rare but can include pancreatitis, gallbladder issues, or dehydration if fluid intake is inadequate